Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

Yin-Feng Kang,Cong Sun,Zhen Zhuang,Run-Yu Yuan,Qingbing Zheng,Jiang-Ping Li,Ping-Ping Zhou,Xin-Chun Chen,Zhe Liu,Xiao Zhang,Xiao-Hui Yu,Xiang-Wei Kong,Qian-Ying Zhu,Qian Zhong,Miao Xu,Nan-Shan Zhong,Yi-Xin Zeng,Guo-Kai Feng,Changwen Ke,Jin-Cun Zhao,Mu-Sheng Zeng

DOI: https://doi.org/10.1021/acsnano.0c08379

IF: 17.1

2021-01-19

ACS Nano

Abstract:The coronavirus disease pandemic of 2019 (COVID-19) caused by the novel SARS-CoV-2 coronavirus resulted in economic losses and threatened human health worldwide. The pandemic highlights an urgent need for a stable, easily produced, and effective vaccine. SARS-CoV-2 uses the spike protein receptor-binding domain (RBD) to bind its cognate receptor, angiotensin-converting enzyme 2 (ACE2), and initiate membrane fusion. Thus, the RBD is an ideal target for vaccine development. In this study, we designed three different RBD-conjugated nanoparticle vaccine candidates, namely, RBD-Ferritin (24-mer), RBD-mi3 (60-mer), and RBD-I53–50 (120-mer), via covalent conjugation using the SpyTag-SpyCatcher system. When mice were immunized with the RBD-conjugated nanoparticles (NPs) in conjunction with the AddaVax or Sigma Adjuvant System, the resulting antisera exhibited 8- to 120-fold greater neutralizing activity against both a pseudovirus and the authentic virus than those of mice immunized with monomeric RBD. Most importantly, sera from mice immunized with RBD-conjugated NPs more efficiently blocked the binding of RBD to ACE2 <i>in vitro</i>, further corroborating the promising immunization effect. Additionally, the vaccine has distinct advantages in terms of a relatively simple scale-up and flexible assembly. These results illustrate that the SARS-CoV-2 RBD-conjugated nanoparticles developed in this study are a competitive vaccine candidate and that the carrier nanoparticles could be adopted as a universal platform for a future vaccine development.This article has not yet been cited by other publications.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a stable, easy - to - produce and effective vaccine in the context of the global COVID - 19 pandemic. Specifically, the paper focuses on the spike protein receptor - binding domain (RBD) of the SARS - CoV - 2 virus, because SARS - CoV - 2 uses RBD to bind to the angiotensin - converting enzyme 2 (ACE2) receptor on host cells, thereby triggering membrane fusion. Therefore, RBD has become an ideal target for vaccine development. Three different RBD - conjugated nanoparticle vaccine candidates, namely RBD - Ferritin (24 - mer), RBD - mi3 (60 - mer) and RBD - I53 - 50 (120 - mer), are designed in the paper and covalently conjugated through the SpyTag - SpyCatcher system. These vaccine candidates show higher neutralizing activity than monomeric RBD in mouse experiments, especially in blocking the binding between RBD and ACE2. In addition, these vaccines have obvious advantages in scale - up production and flexible assembly, indicating that SARS - CoV - 2 RBD - conjugated nanoparticles are a competitive vaccine candidate, and the carrier nanoparticles can be used as a universal platform for future vaccine development.

Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates

Rapid Development of SARS-CoV-2 Receptor Binding Domain-Conjugated Nanoparticle Vaccine Candidate

Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys

Single-component, Self-Assembling, Protein Nanoparticles Presenting the Receptor Binding Domain and Stabilized Spike As SARS-CoV-2 Vaccine Candidates.

Design of a Stabilized RBD Enables Potently Neutralizing SARS-CoV-2 Single-Component Nanoparticle Vaccines

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response

Development of nanoparticle vaccines utilizing designed Fc-binding homo-oligomers and RBD-Fc of SARS-CoV-2

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2

Hydrogel‐Based Slow Release of a Receptor‐Binding Domain Subunit Vaccine Elicits Neutralizing Antibody Responses Against SARS‐CoV‐2

Yeast-expressed Recombinant Protein of the Receptor-Binding Domain in SARS-CoV Spike Protein with Deglycosylated Forms As a SARS Vaccine Candidate

A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge

Hydrogel-based slow release of a receptor-binding domain subunit vaccine elicits neutralizing antibody responses against SARS-CoV-2

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

A Vaccine Based on the Receptor-Binding Domain of the Spike Protein Expressed in Glycoengineered Pichia pastoris Targeting SARS-CoV-2 Stimulates Neutralizing and Protective Antibody Responses

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice